{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:10:06Z","timestamp":1782436206555,"version":"3.54.5"},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Oncology Nursing"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1016\/j.ejon.2008.10.003","type":"journal-article","created":{"date-parts":[[2009,2,8]],"date-time":"2009-02-08T09:29:36Z","timestamp":1234085376000},"page":"49-59","source":"Crossref","is-referenced-by-count":198,"title":["Docetaxel-related side effects and their management"],"prefix":"10.1016","volume":"13","author":[{"given":"Jackie","family":"Baker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffer","family":"Ajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Winther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti S.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejon.2008.10.003_bib1","first-page":"7","article-title":"Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group","volume":"25","author":"Aapro","year":"1998","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib2","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejon.2008.10.003_bib3","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.2006.10.4968","article-title":"Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group","volume":"25","author":"Ajani","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/annonc\/mdl321","article-title":"Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study","volume":"18","author":"Alexandre","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3109\/07357900009012196","article-title":"Managing the neurotoxicity of paclitaxel (Taxol) and docetaxel (Taxotere) with neurotrophic factors","volume":"18","author":"Apfel","year":"2000","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ejon.2008.10.003_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.cad.0000131685.06390.b7","article-title":"Non-allergic nature of docetaxel-induced acute hypersensitivity reactions","volume":"15","author":"Ardavanis","year":"2004","journal-title":"Anticancer Drugs"},{"issue":"18S","key":"10.1016\/j.ejon.2008.10.003_bib7","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.1200\/jco.2007.25.18_suppl.9001","article-title":"A pilot, multi-dose, placebo-controlled evaluation of American ginseng (Panax quinquefolius) to improve cancer-related fatigue: NCCTG trial N03CA","volume":"25","author":"Barton","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/sonc.2001.24602","article-title":"Phase III randomized trial of docetaxel in combination with cisplatin or carboplatin or vinorelbine plus cisplatin in advanced non-small cell lung cancer: interim analysis","volume":"28","author":"Belani","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib9","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1001\/jama.293.19.2367","article-title":"Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer","volume":"293","author":"Brain","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ejon.2008.10.003_bib10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11894-006-0055-z","article-title":"Necrotixing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned","volume":"8","author":"Bremer","year":"2006","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.ejon.2008.10.003_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdj115","article-title":"Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish lung cancer group trial","volume":"17","author":"Camps","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib12","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.2002.07.061","article-title":"Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial","volume":"20","author":"Cascinu","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib13","first-page":"31","article-title":"Taxotere-induced febrile neutropenia management. Hospital management","author":"Chan","year":"2007","journal-title":"Spring"},{"key":"10.1016\/j.ejon.2008.10.003_bib14","first-page":"19","article-title":"Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy","volume":"11","author":"Chan","year":"1997","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.ejon.2008.10.003_bib15","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib16","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1200\/JCO.2006.08.2024","article-title":"Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial","volume":"25","author":"Courneya","year":"2007","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ejca.2005.02.016","article-title":"Docetaxel administration schedule: from fever to tears? A review of randomised studies","volume":"41","author":"Engels","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejon.2008.10.003_bib18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ygyno.2004.11.043","article-title":"Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments","volume":"96","author":"Feldweg","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00000421-200004000-00006","article-title":"Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study","volume":"23","author":"Ferraresi","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib20","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 non-small cell lung cancer study group","volume":"18","author":"Fossella","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib21","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004386.pub2","article-title":"Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy","volume":"19","author":"Gafter-Gvili","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejon.2008.10.003_bib23","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1634\/theoncologist.9-5-538","article-title":"Practical aspects of weekly docetaxel administration schedules","volume":"9","author":"Hainsworth","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.ejon.2008.10.003_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.05.0294","article-title":"Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer","author":"Harvey","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib25","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000104097","article-title":"Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue","volume":"30","author":"Heim","year":"2007","journal-title":"Onkologie"},{"key":"10.1016\/j.ejon.2008.10.003_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1212\/WNL.46.1.104","article-title":"Peripheral neurotoxicity induced by docetaxel","volume":"46","author":"Hilkens","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.ejon.2008.10.003_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1023\/A:1008245400251","article-title":"Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere)","volume":"8","author":"Hilkens","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/bjc.1997.68","article-title":"Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin","volume":"75","author":"Hilkens","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejon.2008.10.003_bib29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jjco\/hym042","article-title":"Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer","volume":"37","author":"Hong","year":"2007","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"Suppl. 3","key":"10.1016\/j.ejon.2008.10.003_bib30","first-page":"iii47","article-title":"Safety profile of docetaxel in patients >65 years of age with metastatic breast cancer: analysis of four phase III studies","volume":"15","author":"Hurria","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(99)06195-4","article-title":"Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer","volume":"355","author":"Ibrahim","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejon.2008.10.003_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clon.2004.09.013","article-title":"Comparison of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (TPF) followed by radiation vs concurrent chemoradiotherapy with TPF in patients with locally advanced squamous cell carcinoma of the head and neck","volume":"17","author":"Katori","year":"2005","journal-title":"Clin. Oncol. (R Coll. Radiol.)"},{"issue":"18S","key":"10.1016\/j.ejon.2008.10.003_bib33","doi-asserted-by":"crossref","first-page":"9004","DOI":"10.1200\/jco.2007.25.18_suppl.9004","article-title":"The cognitive effects of modafinil in breast cancer survivors: a randomised clinical trial","volume":"25","author":"Kohli","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib34","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/BF02967619","article-title":"Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity","volume":"10","author":"Kuroi","year":"2003","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejon.2008.10.003_bib36","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1200\/JCO.2007.10.6583","article-title":"International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients \u2013 an analysis of the medical literature","volume":"25","author":"Lichtman","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/01.JTO.0000263713.38826.8e","article-title":"A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer","volume":"2","author":"Lilenbaum","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib38","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1097\/01.NCC.0000290815.99323.75","article-title":"Fatigue and physical activity in older adults with cancer: a systematic review of the literature","volume":"30","author":"Luctkar-Flude","year":"2007","journal-title":"Cancer Nurs."},{"key":"10.1016\/j.ejon.2008.10.003_bib39","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/sonc.2001.24601","article-title":"Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer","volume":"28","author":"Lynch","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s00520-002-0405-9","article-title":"Managing taxane toxicities","volume":"11","author":"Markman","year":"2003","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ejon.2008.10.003_bib41","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1188\/04.CJON.527-528","article-title":"Chemotherapy-induced nail changes: an unsightly nuisance","volume":"8","author":"Marrs","year":"2004","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.ejon.2008.10.003_bib42","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/annonc\/mdl135","volume":"17","author":"Martin","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib43","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group","volume":"23","author":"Marty","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib44","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1179\/joc.2004.16.1.85","article-title":"Factors predicting docetaxel-related toxicity: experience at a single institution","volume":"16","author":"Massacesi","year":"2004","journal-title":"J. Chemother."},{"key":"10.1016\/j.ejon.2008.10.003_bib45","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2165\/00003495-200565160-00003","article-title":"Docetaxel in hormone-refractory metastatic prostate cancer","volume":"65","author":"McKeage","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ejon.2008.10.003_bib46","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2004.10.163","article-title":"Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?","volume":"22","author":"Minami","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib47","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.apmr.2007.08.110","article-title":"Exercise prevents fatigue and improves quality of life in prostate cancer patients undergoing radiotherapy","volume":"88","author":"Monga","year":"2007","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.ejon.2008.10.003_bib48","article-title":"Docetaxel and fluid retention: use of single-dose dexamethasone","author":"Montoya","year":"2007","journal-title":"ASCO"},{"key":"10.1016\/j.ejon.2008.10.003_bib49","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","article-title":"Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial","volume":"21","author":"Nabholtz","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib50","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-2133.2002.46824.x","article-title":"Nail changes due to docetaxel","volume":"146","author":"Pavithran","year":"2002","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejon.2008.10.003_bib52","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1634\/theoncologist.11-5-520","article-title":"Teams: communication in multidisciplinary care","volume":"11","author":"Penson","year":"2006","journal-title":"Oncologist"},{"key":"10.1016\/j.ejon.2008.10.003_bib53","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.1997.15.9.3149","article-title":"Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer","volume":"15","author":"Piccart","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib54","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1080\/02841860310022977","article-title":"Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxel","volume":"43","author":"Poikonen","year":"2004","journal-title":"Acta Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib55","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00001813-199810000-00003","article-title":"Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel","volume":"9","author":"Pronk","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejon.2008.10.003_bib56","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/01.JTO.0000268672.57002.69","article-title":"Survival without common toxicity criteria grade 3\/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis","volume":"2","author":"Pujol","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib57","author":"Remenar","year":"2006","journal-title":"ASCO"},{"key":"10.1016\/j.ejon.2008.10.003_bib58","year":"2007","journal-title":"Taxotere 20mg and 80mg concentrate and solvent for infusion: summary of product characteristics"},{"key":"10.1016\/j.ejon.2008.10.003_bib59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/annonc\/mdi058","article-title":"Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin\/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer","volume":"16","author":"Schwartz","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib60","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1200\/JCO.2005.15.651","article-title":"Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand","volume":"23","author":"Scott\u00e9","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"18S","key":"10.1016\/j.ejon.2008.10.003_bib61","doi-asserted-by":"crossref","first-page":"9059","DOI":"10.1200\/jco.2007.25.18_suppl.9059","article-title":"Frozen sock use in the prevention of docetaxel-induced nails and skin toxicities: Results of a case-control study","volume":"25","author":"Scott\u00e9","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib62","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.1998.16.10.3426","article-title":"Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment","volume":"16","author":"Semb","year":"1998","journal-title":"J.\u00a0Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ejon.2008.10.003_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005010.pub2","article-title":"Chemotherapy for hormone-refractory prostate cancer","author":"Shelley","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejon.2008.10.003_bib64","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib65","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0093-7754(01)90297-0","article-title":"Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials","volume":"28","author":"Shepherd","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib66","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib67","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/A:1008211226339","article-title":"Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial","volume":"8","author":"Smyth","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib68","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1185\/030079905X65411","article-title":"A randomized trial assessing the utility of a test-dose program with taxanes","volume":"21","author":"Stanford","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejon.2008.10.003_bib69","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejon.2008.10.003_bib70","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.2005.03.082","article-title":"Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly","volume":"23","author":"ten Tije","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib71","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib72","first-page":"81","article-title":"Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer","volume":"12","author":"van Poppel","year":"2005","journal-title":"Can. J. Urol."},{"key":"10.1016\/j.ejon.2008.10.003_bib73","article-title":"Pegfilgrastim\u00b1ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study","author":"von Minckwitz","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib74","first-page":"73","article-title":"The EORTC-ECTG experience with acute hypersensitivity reactions in Taxotere studies","volume":"12","author":"Wanders","year":"1993","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ejon.2008.10.003_bib75","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S0140-6736(00)04210-0","article-title":"Clinical picture: nail changes secondary to docetaxel","volume":"357","author":"Wasner","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejon.2008.10.003_bib76","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00520-007-0232-0","article-title":"Nail changes due to docetaxel \u2013 a neglected side effect and nuisance for the patient","volume":"15","author":"Winther","year":"2007","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ejon.2008.10.003_bib77","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/00002018-200124100-00005","article-title":"Prevention and management of antineoplastic-induced hypersensitivity reactions","volume":"24","author":"Zanotti","year":"2001","journal-title":"Drug Saf."}],"container-title":["European Journal of Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388908001324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1462388908001324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T13:42:48Z","timestamp":1589550168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1462388908001324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["S1462388908001324"],"URL":"https:\/\/doi.org\/10.1016\/j.ejon.2008.10.003","relation":{},"ISSN":["1462-3889"],"issn-type":[{"value":"1462-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}